About Statin
Statin is a structural analog of HMG-CoA enzyme and is effective in reducing LDL. It shows its pharmaceutical action by inhibiting the key enzyme involved in cholesterol synthesis, which is called HMG-CoA reductase. Therefore, statin is referred to HMG-CoA reductase inhibitors. Statin has been associated with a beneficial effect on cardiovascular morbidity and mortality. It has significant anti-inflammatory and plaque-stabilizing effects. Its other effects include decreased oxidative stress and vascular inflammation with increased atherosclerotic lesions. Some of the currently available statins are atorvastatin, lovastatin, rosuvastatin, and simvastatin.
Technavio's analysts forecast the global statin market to decline at a CAGR of 7.50% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global statin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of statins used for the management of lipid abnormalities and lipid-associated comorbidities such as stroke and coronary heart disease. This report provides a discussion of the market in the following three regions: Americas, APAC, and EMEA.
Technavio's report, Global Statin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Merck
• Novartis
• Pfizer
Other Prominent Vendors
• Amgen
• Aurobindo Pharma
• Abbvie
• Abbott
• Biocon
• BC World Pharm
• Cipla
• Concord Biotech
• CKD Bio
• CJ HealthCare Corporation
• Cerenis Therapeutics
• GlaxoSmithKline
• HanAll BioPharma
• JX Pharmaceuticals
• Kowa
• Lupin
• Livzon
• Mylan
• Merz Pharmaceuticals
• SUN Pharma
• Teva
• Torrent Pharmaceuticals
• Zydus Cadila
Market Driver
• Rising Number of High Cholesterol Cases
• For a full, detailed list, view our report
Market Challenge
• Lack of Novel Molecules in Statins Category
• For a full, detailed list, view our report
Market Trend
• Switch from Statins to Non-statins
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Product Profile
05.1 Crestor
05.2 Caduet
05.3 Lescol
05.4 Lipitor
05.5 Liptruzet
05.6 Mevacor
05.7 Vytorin
05.8 Zocor
06. Introduction
07. Statin: An Overview
07.1 Statin Pharmacophore
07.2 Mechanism of Action
07.2.1 Different Class of Lipoproteins
07.3 Clinical Application
07.4 Treatment Guidelines
08. Pipeline Portfolio
08.1 HL040
08.2 Livasartan
08.3 BCWP-C001
08.4 CJ-30056
09. Market Landscape
09.1 Market Overview
09.1.1 Market Size and Forecast
09.2 Statin Market in US 2014-2019
09.2.1 Market Size and Forecast
09.3 Five Forces Analysis
10. Market Segmentation by Product Category
10.1 Type 1 Statins
10.1.1 Lovastatin
10.1.2 Pravastatin
10.1.3 Simvastatin
10.2 Type 2 Statins
10.2.1 Atorvastatin
10.2.2 Fluvastatin
10.2.3 Rosuvastatin
11. Geographical Segmentation
11.1 Global Statin Market by Geographical Segmentation 2014-2019
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 AstraZeneca
19.2.2 Merck
19.2.3 Novartis
19.2.4 Pfizer
19.3 Other Prominent Vendors
20. Key Vendor Analysis
20.1 AstraZeneca
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2013
20.1.4 Business Segmentation by Revenue 2011-2013
20.1.5 Sales by Geography
20.1.6 Business Strategy
20.1.7 Key Developments
20.1.8 SWOT Analysis
20.2 Merck
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation by Revenue 2013
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Business Strategy
20.2.7 Key Developments
20.2.8 SWOT Analysis
20.3 Novartis
20.3.1 Key Facts
20.3.2 Business Description
20.3.3 Business Segmentation
20.3.4 Revenue by Business Segmentation
20.3.5 Revenue Comparison 2012 and 2013
20.3.6 Sales by Geography
20.3.7 Business Strategy
20.3.8 Key Developments
20.3.9 SWOT Analysis
20.4 Pfizer
20.4.1 Key facts
20.4.2 Business Overview
20.4.3 Business Segmentation by Revenue 2014
20.4.4 Business Segmentation by Revenue 2013 and 2014
20.4.5 Geographical Segmentation by Revenue 2014
20.4.6 Business Strategy
20.4.7 Key Developments
20.4.8 SWOT Analysis
21. Other Reports in this Series
List Of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Pictorial Representation of Statin Pharmacophore
Exhibit 3: Schematic Representation of Statin and Effect on Cholesterol Synthesis
Exhibit 4: Evaluation of Lipoprotein Levels based on ATP III Classification
Exhibit 5: Diagrammatic Representation of Pipeline Molecules for Lipid Management
Exhibit 6: Global Statin Market 2014-2019 ($ millions)
Exhibit 7: Statin Market in US 2014-2019 ($ millions)
Exhibit 8: Global Statin Market Segmentation by Molecule Type
Exhibit 9: Segmentation of Global Statin Market by Geography 2014
Exhibit 10: Arguments For and Against OTC Switch by Pharmaceutical Companies and Regulatory Organizations
Exhibit 11: Crestor: YoY Global Revenue 2010-2014 ($ millions)
Exhibit 12: AstraZeneca: Key Takeaways
Exhibit 13: Vytorin: YoY Global Revenue of 2010-2014 ($ millions)
Exhibit 14: Zocor: YoY Global Revenue 2010-2014 ($ millions)
Exhibit 15: Merck: Key Takeaways
Exhibit 16: Lipitor: YoY Global Revenue of 2010-2014 ($ millions)
Exhibit 17: Pfizer: Key Takeaways
Exhibit 18: AstraZeneca: Business Segmentation by Revenue 2013
Exhibit 19: AstraZeneca: Business Segmentation by Revenue 2011-2013 ($ millions)
Exhibit 20: AstraZeneca: Sales by Geography 2013
Exhibit 21: Merck: Business Segmentation by Revenue 2013
Exhibit 22: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billions)
Exhibit 23: Merck: Sales by Geography 2013
Exhibit 24: Novartis: Business Segmentation
Exhibit 25: Novartis: Revenue by Business Segmentation 2013
Exhibit 26: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
Exhibit 27: Novartis: Revenue by Geographical Segmentation 2013
Exhibit 28: Pfizer: Business Segmentation by Revenue 2014
Exhibit 29: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
Exhibit 30: Pfizer: Geographical Segmentation by Revenue 2014
